RheinBio announced that net profit for the first half of 2026 is expected to be 495.43 million yuan to 609.76 million yuan, an increase of 30% to 60% over the previous year. The main reason is that, on the one hand, the company continues to improve product quality, enhance customer stickiness, and promote steady year-on-year revenue growth; on the other hand, the company continuously optimizes its product structure, and its comprehensive gross margin has recovered to a certain extent compared to the same period last year. The year-on-year increase in revenue and the improvement in gross profit simultaneously drove the company's performance in the reporting period to achieve higher growth.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.